|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.59 USD | -0.87% |
|
-7.40% | -8.14% |
| 14/01 | BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says | MT |
| 13/01 | BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -1.09 | -0.78 | 0.46 | 1.63 | 5.15 | |||||
Return on Total Capital | -1.24 | -0.87 | 0.52 | 1.82 | 5.76 | |||||
Return On Equity % | 23.77 | -1.53 | 3.19 | 3.51 | 8.05 | |||||
Return on Common Equity | 23.77 | -1.53 | 3.19 | 3.51 | 8.05 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 38.06 | 40.46 | 45.93 | 47.85 | 79.67 | |||||
SG&A Margin | 39.65 | 41.13 | 40.74 | 38.16 | 32 | |||||
EBITDA Margin % | 0.72 | 1.83 | 7.06 | 11.43 | 23.35 | |||||
EBITA Margin % | -1.59 | -0.67 | 5.19 | 9.68 | 21.49 | |||||
EBIT Margin % | -4.93 | -4.03 | 2.19 | 7.11 | 19.97 | |||||
Income From Continuing Operations Margin % | 46.18 | -3.47 | 6.75 | 6.93 | 14.96 | |||||
Net Income Margin % | 46.18 | -3.47 | 6.75 | 6.93 | 14.96 | |||||
Net Avail. For Common Margin % | 46.18 | -3.47 | 6.75 | 6.93 | 14.96 | |||||
Normalized Net Income Margin | -3.29 | -2.28 | 1.37 | 5.87 | 13.74 | |||||
Levered Free Cash Flow Margin | -1.01 | 10.56 | 6.29 | -1.07 | 9.51 | |||||
Unlevered Free Cash Flow Margin | -0.02 | 11.08 | 6.77 | -0.62 | 9.79 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.35 | 0.31 | 0.34 | 0.37 | 0.41 | |||||
Fixed Assets Turnover | 1.72 | 1.7 | 1.91 | 2.17 | 2.61 | |||||
Receivables Turnover (Average Receivables) | 4.51 | 4.49 | 5.02 | 4.42 | 4.41 | |||||
Inventory Turnover (Average Inventory) | 1.67 | 1.49 | 1.36 | 1.26 | 0.5 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.76 | 4.21 | 4.67 | 2.51 | 5.33 | |||||
Quick Ratio | 3.07 | 2.57 | 2.98 | 1.45 | 2.96 | |||||
Operating Cash Flow to Current Liabilities | 0.17 | 0.56 | 0.3 | 0.14 | 0.94 | |||||
Days Sales Outstanding (Average Receivables) | 81.22 | 81.23 | 72.68 | 82.61 | 82.99 | |||||
Days Outstanding Inventory (Average Inventory) | 218.96 | 244.91 | 269.05 | 289.49 | 737.96 | |||||
Average Days Payable Outstanding | 67.6 | 59.59 | 62.88 | 67.66 | 142.86 | |||||
Cash Conversion Cycle (Average Days) | 232.59 | 266.55 | 278.85 | 304.44 | 678.09 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 27.55 | 26.3 | 24.33 | 22.9 | 11.2 | |||||
Total Debt / Total Capital | 21.6 | 20.83 | 19.57 | 18.63 | 10.08 | |||||
LT Debt/Equity | 27.27 | 26.06 | 24.1 | 12.75 | 11.07 | |||||
Long-Term Debt / Total Capital | 21.38 | 20.63 | 19.39 | 10.37 | 9.96 | |||||
Total Liabilities / Total Assets | 29.79 | 28.86 | 27.79 | 27.63 | 19.04 | |||||
EBIT / Interest Expense | -3.13 | -4.85 | 2.88 | 9.93 | 45.01 | |||||
EBITDA / Interest Expense | 0.9 | 3.11 | 10.12 | 16.77 | 53.74 | |||||
(EBITDA - Capex) / Interest Expense | -3 | -3.12 | 2.54 | 11.19 | 46.99 | |||||
Total Debt / EBITDA | 43.1 | 23.56 | 6.93 | 3.9 | 0.93 | |||||
Net Debt / EBITDA | 2.51 | 2.3 | -1.06 | 0.21 | -0.74 | |||||
Total Debt / (EBITDA - Capex) | -12.85 | -23.46 | 27.56 | 5.85 | 1.07 | |||||
Net Debt / (EBITDA - Capex) | -0.75 | -2.29 | -4.22 | 0.31 | -0.85 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 9.18 | -0.76 | 13.53 | 15.42 | 17.97 | |||||
Gross Profit, 1 Yr. Growth % | 12.47 | 5.49 | 28.89 | 20.24 | 20.48 | |||||
EBITDA, 1 Yr. Growth % | 2.93T | 151.45 | 338.65 | 61.75 | 129.69 | |||||
EBITA, 1 Yr. Growth % | -42.44 | -58 | -976.05 | 77.82 | 147.34 | |||||
EBIT, 1 Yr. Growth % | -12.49 | -19.01 | -161.85 | 149.55 | 206.85 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -3.7T | -107.46 | -320.91 | 18.43 | 154.62 | |||||
Net Income, 1 Yr. Growth % | -3.7T | -107.46 | -320.91 | 18.43 | 154.62 | |||||
Normalized Net Income, 1 Yr. Growth % | -1.35 | -31.21 | -168.29 | 229.19 | 211.98 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -3.5T | -107.74 | -314.01 | 16 | 153.71 | |||||
Accounts Receivable, 1 Yr. Growth % | 18.8 | -16.72 | 23.54 | 37.37 | 4.23 | |||||
Inventory, 1 Yr. Growth % | 2.69 | 11.18 | 15.12 | 23.83 | 11.33 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.8 | -0.71 | 3 | -0.19 | -3.18 | |||||
Total Assets, 1 Yr. Growth % | 24.69 | 2.66 | 6.17 | 7.32 | 2.15 | |||||
Tangible Book Value, 1 Yr. Growth % | 41.47 | 5.54 | 10.53 | 8.89 | 15.9 | |||||
Common Equity, 1 Yr. Growth % | 31.5 | 4.01 | 7.91 | 7.57 | 14.27 | |||||
Cash From Operations, 1 Yr. Growth % | 76.88 | 256.75 | -42.24 | -9.46 | 259.69 | |||||
Capital Expenditures, 1 Yr. Growth % | -21.18 | -16.39 | 26.56 | -20.06 | -11.65 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -85.91 | -1.14T | -34.59 | -117.71 | -1.67T | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -99.62 | -45.45T | -32.83 | -109.64 | -4.39T | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 11.7 | 4.09 | 6.14 | 14.47 | 16.69 | |||||
Gross Profit, 2 Yr. CAGR % | 21.5 | 8.92 | 16.61 | 24.49 | 19.47 | |||||
EBITDA, 2 Yr. CAGR % | -52.46 | 772.5 | 232.11 | 186.33 | 106.27 | |||||
EBITA, 2 Yr. CAGR % | -51.32 | -50.83 | 91.82 | 334.42 | 128.49 | |||||
EBIT, 2 Yr. CAGR % | -23.06 | -15.81 | -29.23 | 52.18 | 222.88 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 233.57 | 63.92 | -59.29 | 61.75 | 73.65 | |||||
Net Income, 2 Yr. CAGR % | 233.57 | 63.92 | -59.29 | 61.75 | 73.65 | |||||
Normalized Net Income, 2 Yr. CAGR % | -25.05 | -17.62 | -31.46 | 83.65 | 280.8 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 220.86 | 62.2 | -59.17 | 57.56 | 71.55 | |||||
Accounts Receivable, 2 Yr. CAGR % | 14.39 | -0.53 | 1.44 | 30.27 | 19.66 | |||||
Inventory, 2 Yr. CAGR % | 14.71 | 6.85 | 13.13 | 19.4 | 17.42 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.17 | 0.54 | 1.13 | 1.39 | -1.7 | |||||
Total Assets, 2 Yr. CAGR % | 14.93 | 13.14 | 4.41 | 6.74 | 4.7 | |||||
Tangible Book Value, 2 Yr. CAGR % | 23.79 | 22.19 | 7.93 | 9.71 | 12.34 | |||||
Common Equity, 2 Yr. CAGR % | 17.62 | 16.95 | 5.88 | 7.74 | 10.87 | |||||
Cash From Operations, 2 Yr. CAGR % | 105.53 | 151.2 | 43.55 | -27.68 | 80.46 | |||||
Capital Expenditures, 2 Yr. CAGR % | -11.09 | -18.82 | 2.87 | 0.58 | -15.96 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -47.22 | 20.98 | 165.07 | -64.16 | 40.62 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -89.39 | 31.36 | 1.67T | -73.29 | 37.74 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.3 | 7.38 | 7.15 | 9.15 | 15.62 | |||||
Gross Profit, 3 Yr. CAGR % | 15.37 | 15.91 | 15.21 | 17.8 | 44.92 | |||||
EBITDA, 3 Yr. CAGR % | -31.37 | -17.17 | 593.77 | 174.19 | 170.36 | |||||
EBITA, 3 Yr. CAGR % | -31.79 | -53.66 | 28.42 | 99.38 | 266.93 | |||||
EBIT, 3 Yr. CAGR % | -9.44 | -21.74 | -24.04 | 23.32 | 97.22 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 94.34 | -6.02 | 81.06 | -41.88 | 88.16 | |||||
Net Income, 3 Yr. CAGR % | 94.34 | -6.02 | 81.06 | -41.88 | 88.16 | |||||
Normalized Net Income, 3 Yr. CAGR % | -12.88 | -27.16 | -22.62 | 32.38 | 110.46 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 88.93 | -7.27 | 77.9 | -42.17 | 84.68 | |||||
Accounts Receivable, 3 Yr. CAGR % | 19.71 | 2.91 | 6.92 | 12.22 | 20.94 | |||||
Inventory, 3 Yr. CAGR % | 13.66 | 13.52 | 9.54 | 16.59 | 16.65 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 6.71 | 4.48 | 1.35 | 0.69 | -0.16 | |||||
Total Assets, 3 Yr. CAGR % | 8.07 | 10.69 | 10.77 | 5.37 | 5.19 | |||||
Tangible Book Value, 3 Yr. CAGR % | 18.59 | 17.38 | 18.12 | 8.25 | 11.73 | |||||
Common Equity, 3 Yr. CAGR % | 13.49 | 12.9 | 13.81 | 6.44 | 9.87 | |||||
Cash From Operations, 3 Yr. CAGR % | 113.62 | 147 | 53.89 | 23.1 | 23.44 | |||||
Capital Expenditures, 3 Yr. CAGR % | -16.9 | -12.9 | -5.87 | -5.43 | -3.67 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -41.99 | 42.5 | -0.33 | 11.33 | 10.44 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -81.34 | 72.16 | 6.17 | 222.05 | 9.79 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.89 | 10.58 | 9.8 | 10.16 | 10.86 | |||||
Gross Profit, 5 Yr. CAGR % | 47.02 | 24.94 | 15.86 | 19.27 | 29.28 | |||||
EBITDA, 5 Yr. CAGR % | -44.85 | -27.17 | 28.95 | 36.03 | 331.99 | |||||
EBITA, 5 Yr. CAGR % | -37.06 | -44.29 | 3.15 | 13.44 | 64.22 | |||||
EBIT, 5 Yr. CAGR % | -21.61 | -22.24 | -17.95 | 2.11 | 40.3 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 37.98 | -36.69 | 3.88 | 16.77 | 78.06 | |||||
Net Income, 5 Yr. CAGR % | 37.98 | -36.69 | 3.88 | 16.77 | 78.06 | |||||
Normalized Net Income, 5 Yr. CAGR % | -22.67 | -25.28 | -20.85 | 5.44 | 44.62 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 33.34 | -37.95 | 2.25 | 14.63 | 75.34 | |||||
Accounts Receivable, 5 Yr. CAGR % | 22.14 | 11.64 | 12.03 | 13.09 | 11.85 | |||||
Inventory, 5 Yr. CAGR % | 20.79 | 16.94 | 13.45 | 15.84 | 12.62 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 9.12 | 6.26 | 4.44 | 3.23 | 0.12 | |||||
Total Assets, 5 Yr. CAGR % | 9.41 | 8.33 | 6.59 | 9.1 | 8.3 | |||||
Tangible Book Value, 5 Yr. CAGR % | 18.11 | 12.83 | 14.2 | 14.22 | 15.77 | |||||
Common Equity, 5 Yr. CAGR % | 11.33 | 9.07 | 10.39 | 10.78 | 12.63 | |||||
Cash From Operations, 5 Yr. CAGR % | -17.21 | 5.97 | 82.21 | 51.12 | 64.02 | |||||
Capital Expenditures, 5 Yr. CAGR % | -12.87 | -8.42 | -9.5 | -7.74 | -10.04 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -25.75 | -6.21 | 6.53 | -17.4 | 15.31 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -62.31 | -3.47 | 15.36 | -17.77 | 18.71 |
- Stock Market
- Equities
- BMRN Stock
- Financials BioMarin Pharmaceutical Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















